LYON, France, September 7, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies, today announced that management will present at the following investor conferences during the month of September 2021: H.C.
Total revenue for the first half 2021 of EUR 20.7 million (USD $24.8 million) increased 22.5% over the same period of the prior year Net income was EUR 0.4 million (USD 0.4 million), or EUR 0.01 per diluted share, for the first half of 2021 Cash balance of EUR 45 million (USD $53.3 million) as of
Total company second quarter 2021 revenue of approximately EUR 10.4 million (USD $12.4 million) increased 11.8% year-over-year; first half 2021 total company revenue of EUR 20.7 million (USD $24.8 million) increased 22.5% During the second quarter, U.S.
Successful financing and hiring of MedTech industry veteran Ryan Rhodes to drive accelerated U.S. expansion efforts LYON, France, July 20, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today issued the following letter to shareholders: To
Appointment brings highly experienced medical technology and commercialization leader to drive EDAP’s US expansion focus. Career accomplishments include 14 years at Intuitive Surgical, where he played a leading role in global clinical expansion of robotic surgery in multiple specialties including
Generated record first quarter revenue of EUR 10.3 million (USD 12.4 million), an increase of 35.4% year-over-year Increased gross margin year-over-year to 42.4%, contributing to a profitable quarter Raised gross proceeds of approximately $28 million through an underwritten offering of American
Company to host conference call and webcast on Wednesday , May 12 at 8:30 am EDT LYON, France, May 4 , 20 2 1 - EDAP TMS SA (Nasdaq: EDAP), a global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2021 after
LYON, France, April 23, 2021 -- EDAP TMS S.A. (NASDAQ: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced that the price of its offering of American Depositary Shares (“ADS”) has been set at $6.75 per ADS and that the number of offered ADSs is 4,150,000 for an
LYON, France, April 22, 2021 -- EDAP TMS S.A. (NASDAQ: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today the launch of a follow-on public offering of its American Depositary Shares, or ADSs, each representing one ordinary share of the Company.
Generated record fourth quarter revenue of EUR 15.4 million ( USD 18.3 million ), an increase of 28% year-over-year; HIFU revenue up 51% year-over-year Generated €41.7 million revenue and profitable operating result for the full year 2020. Completed sales to renowned healthcare institutions, such
